Antonia Digklia

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


73 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
Sous presse
 
Prognostic value of CT-based skeletal muscle and adipose tissue mass and quality parameters in patients with liver metastases and intrahepatic cholangiocarcinoma undergoing Yttrium-90 radioembolization.
Zhao Y., Becce F., Balmer R., do Amaral R.H., Alemán-Gómez Y., Uldry E., Fraga M., Tsoumakidou G., Villard N., Denys A. et al. European radiology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E99EF0B1B695]
2024
 
Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis.
Voutsadakis I.A., Kokkali S., Digklia A., 2024/12. Clinical colorectal cancer, 23 (4) pp. 318-325.e1. Peer-reviewed.
[DOI][Pmid][serval:BIB_B150D8B52D32]
Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.
Laureline W., Patrick O., Tu N., Stephane C., Ana D., Daniela F., Chiara S., Igor L., Antonia D., 2024/11. Skeletal radiology, 53 (11) pp. 2537-2543. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22489F1FC523]
Abscopal effect induced by cryoablation in a 55-year-old patient with metastatic dedifferentiated liposarcoma: a case report.
Wetterwald L., Papadopoulos S., Tsoumakidou G., Boughdad S., Ferraro D., Koulouris P., Cherix S., Duran R., Digklia A., 2024/10/20. Annals of translational medicine, 12 (5) p. 94. Peer-reviewed.
[DOI][Pmid][serval:BIB_A8DBBBAB3929]
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review.
Pozzessere C., Mazini B., Omoumi P., Jreige M., Noirez L., Digklia A., Fasquelle F., Sempoux C., Dromain C., 2024/07/19. Cancers, 16 (14). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21C90DDD7652]
 
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A., Pagkali A., Kotsantis I., Economopoulou P., Kyrkasiadou M., Moutafi M., Gavrielatou N., Anastasiou M., Boulouta A., Pantazopoulos A. et al., 2024/04. Cancer treatment reviews, 125 p. 102716. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB408536C633]
Anatomical Quantitative Volumetric Evaluation of Liver Segments in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy: Key Parameters Influencing Untreated Liver Hypertrophy.
Girardet R., Knebel J.F., Dromain C., Vietti Violi N., Tsoumakidou G., Villard N., Denys A., Halkic N., Demartines N., Kobayashi K. et al., 2024/01/30. Cancers, 16 (3). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_190E90C12E5E]
CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas.
Bakaric A., Cironi L., Praz V., Sanalkumar R., Broye L.C., Favre-Bulle K., Letovanec I., Digklia A., Renella R., Stamenkovic I. et al., 2024/01/21. Cancers, 16 (2) p. 457. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6DD2EB3D2A00]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C., Cardoso E., Locatelli I., Zaman K., Diciolla A., Digklia A., Stravodimou A., Cristina V., Aedo-Lopez V., Dolcan A. et al., 2024. PloS one, 19 (6) pp. e0304573. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43D02C36CEB4]
A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy.
Rivera J., Digklia A., Christou A.S., Anibal J., Vallis K.A., Wood B.J., Stride E., 2024/01. Ultrasound in medicine & biology, 50 (1) pp. 1-7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E69D2EA7A395]
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A., Kollár A., Dietrich D., Kronig M.N., Britschgi C., Rordorf T., Joerger M., Krasniqi F., Metaxas Y., Colombo I. et al., 2024/01. European journal of cancer, 197 p. 113470. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4C4A8A8D1EB]
2023
 
Diagnostic et prise en charge de la tumeur à cellules géantes ténosynoviale [Diagnosis and management of tenosynovial giant cell tumor]
Bakota-Morrison C., Strasser R., Letovanec I., Digklia A., Stamatiou A., Omoumi P., Cherix S., 2023/12/13. Revue medicale suisse, 19 (854) pp. 2330-2335. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E70F81166152]
 
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q., Klein C., Caruso S., Maille P., Allende D.S., Mínguez B., Iavarone M., Ningarhari M., Casadei-Gardini A., Pedica F. et al., 2023/12. The Lancet. Oncology, 24 (12) pp. 1411-1422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B5A44DC3272]
99mTc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy.
Tabotta F., Gnesin S., Dunet V., Ponti A., Digklia A., Boughdad S., Schaefer N., Prior J.O., Villard N., Tsoumakidou G. et al., 2023/08/12. Scientific reports, 13 (1) p. 13118. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21F17BF36DB0]
Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.
Digklia A., Dolcan A., Kucharczyk M.A., Jones R.L., Napolitano A., 2023/06. Cancer management and research, 15 pp. 537-545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A99279E44987]
 
The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer.
Voutsadakis I.A., Digklia A., 2023/03/03. Current issues in molecular biology, 45 (3) pp. 2105-2120. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5BA72940A3F2]
 
Clear cell sarcoma: state-of-the art and perspectives.
Wetterwald L., Riggi N., Kyriazoglou A., Dei Tos G., Dei Tos A., Digklia A., 2023/03. Expert review of anticancer therapy, 23 (3) pp. 235-242. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E565DF943C91]
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis I.A., Digklia A., 2023/02. Chinese clinical oncology, 12 (1) p. 2. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_173A16DC9A8B]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
 
Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz A.M., Boughdad S., Vietti-Violi N., Digklia A., Dromain C., Dunet V., Duran R., 2023. Frontiers in immunology, 14 p. 1133207. Peer-reviewed.
[DOI][Pmid][serval:BIB_8384233B2788]
 
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Haber P.K., Castet F., Torres-Martin M., Andreu-Oller C., Puigvehí M., Miho M., Radu P., Dufour J.F., Verslype C., Zimpel C. et al., 2023/01. Gastroenterology, 164 (1) pp. 72-88.e18. Peer-reviewed.
[DOI][Pmid][serval:BIB_5E664B01B65D]
2022
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
Digklia A., Boughdad S., Homicsko K., Dromain C., Trimech M., Dolcan A., Peters S., Prior J., Schaefer N., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005383. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_923D116CD173]
Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.
Psilopatis I., Kokkali S., Palamaris K., Digklia A., Vrettou K., Theocharis S., 2022/09/24. International journal of molecular sciences, 23 (19) p. 11271. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6378E1D11BD]
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M., Warlaumont M., Berger M.D., Däster S., Delaloye R., Digklia A., Gloor B., Fritsch R., Koeberle D., Koessler T. et al., 2022/09/01. Cancers, 14 (17) p. 4275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62CF2A596AB9]
Inflammatory Myofibroblastic Tumour: State of the Art.
Gros L., Dei Tos A.P., Jones R.L., Digklia A., 2022/07/27. Cancers, 14 (15) p. 3662. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BF48E08DCCE9]
Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels [Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm]
Undurraga M., Mathevet P., Hubner M., Buchs N.C., Warlaumont M., Sarivalasis A., Diciolla A., Lang N., Koessler T., Digklia A. et al., 2022/05/18. Revue medicale suisse, 18 (782) pp. 990-996. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_521D9B8BA734]
 
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A., Coukos G., Homicsko K., 2022/05/02. Clinical cancer research, 28 (9) pp. 1745-1747. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CAC463D4200]
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma.
Möller E., Praz V., Rajendran S., Dong R., Cauderay A., Xing Y.H., Lee L., Fusco C., Broye L.C., Cironi L. et al., 2022/04/27. Nature communications, 13 (1) p. 2267. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_73886BC749BC]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Teixeira Farinha H., Digklia A., Schizas D., Demartines N., Schäfer M., Mantziari S., 2022/01/22. Cancers, 14 (3) p. 554. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B02180461EEC]
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Papadopoulos S., Koulouris P., Royer-Chardon C., Tsoumakidou G., Dolcan A., Cherix S., Matter M., Omoumi P., Digklia A., 2022. Frontiers in endocrinology, 13 p. 794512. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F80FCDEF66D]
Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips E., Jones R.L., Huang P., Digklia A., 2022. Frontiers in pharmacology, 13 p. 869754. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BAD5D07E845B]
Gallbladder cancer during pregnancy treated with surgery and adjuvant gemcitabine: A case report and review of the literature.
Diciolla A., Gianoni M., Fleury M., Szturz P., Demartines N., Peters S., Duran R., Desseauve D., Panchaud M.A., Fasquelle F. et al., 2022. Frontiers in oncology, 12 p. 1006387. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83C6E9C8B673]
2021
Prise en charge des sarcomes des tissus mous abdominaux [Management of abdominal soft tissue sarcomas]
Djafarrian R., Zingg T., Digklia A., Becce F., Özsahin E.M., La Rosa S., Demartines N., Matter M., 2021/06/16. Revue medicale suisse, 17 (743) pp. 1172-1176. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B1CF53F8316E]
 
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.
Kokkali S., Stravodimou A., Duran-Moreno J., Koufopoulos N., Voutsadakis I.A., Digklia A., 2021/06. Expert review of anticancer therapy, 21 (6) pp. 591-604. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A06BD9846D13]
Oncologie [2020 oncology update]
Dei Tos G., Galli Vareia I., Huber A., Wolf B., Diciolla A., Herrera Gomez R.G., Wagner D., Digklia A., Bouchaab H., Cristina V. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 201-205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_25D6152EB267]
Case Report: Vasculitis Triggered by SIRT in a Patient With Previously Untreated Cholangiocarcinoma.
Stamatiou A., Jankovic J., Szturz P., Fasquelle F., Duran R., Schaefer N., Diciolla A., Digklia A., 2021. Frontiers in oncology, 11 p. 755750. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_441991FCB38E]
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Gros L., Szturz P., Diciolla A., Kirchner V., Peters S., Schaefer N., Hubner M., Digklia A., 2021. Frontiers in oncology, 11 p. 704295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E9DC9323568E]
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR Research Protocols, 10 (6) pp. e30090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7657CD7990C9]
2020
Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium.
Girardet R., Boughdad S., Digklia A., Beigelman C., Meyer M., Schaefer N., Vermersch M., Hocquelet A., Tsoumakidou G., Denys A. et al., 2020/11. Cardiovascular and interventional radiology, 43 (11) pp. 1712-1715. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_026A056D5150]
Interventional oncology at the time of COVID-19 pandemic: Problems and solutions.
Denys A., Guiu B., Chevallier P., Digklia A., de Kerviler E., de Baere T., 2020/06. Diagnostic and interventional imaging, 101 (6) pp. 347-353. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BF6D342B5BAB]
Published Erratum: LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma.
Keskin T., Bakaric A., Waszyk P., Boulay G., Torsello M., Cornaz-Buros S., Chevalier N., Geiser T., Martin P., Volorio A. et al., 2020/04/14. Cell reports, 31 (2) p. 107539. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_69BFEDF2908B]
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.
Keskin T., Bakaric A., Waszyk P., Boulay G., Torsello M., Cornaz-Buros S., Chevalier N., Geiser T., Martin P., Volorio A. et al., 2020/03/31. Cell reports, 30 (13) pp. 4567-4583.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EAA705D7C5B5]
 
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.
Ponti A., Denys A., Digklia A., Schaefer N., Hocquelet A., Knebel J.F., Michielin O., Dromain C., Duran R., 2020/03. Journal of nuclear medicine, 61 (3) pp. 350-356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FD86FE51A57]
 
Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.
Duran-Moreno J., Kokkali S., Ramfidis V., Salomidou M., Digklia A., Koumarianou A., Tomos P., Koufopoulos N., Vamvakaris I., Psychogiou E. et al., 2020/03. Anticancer research, 40 (3) pp. 1697-1703. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15EF81B04AF1]
Imaging of tumour response to immunotherapy.
Dromain C., Beigelman C., Pozzessere C., Duran R., Digklia A., 2020/01/03. European radiology experimental, 4 (1) p. 2. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_152AC98411BD]
2019
 
Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.
Policicchio A., Mercier J., Digklia A., Voutsadakis I.A., 2019/12. Journal of gastrointestinal cancer, 50 (4) pp. 894-900. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9FB09F99885C]
Synchronous tumors of the pancreas and the gallbladder: a case report with targeted NGS evaluation.
Sivade A., Sempoux C., Voutsadakis I., Brunel C., Halkic N., Godat S., Duran R., Digklia A., 2019/11. Annals of translational medicine, 7 (22) p. 696. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2C6527444F7B]
 
Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.
Digklia A., Duran R., Homicsko K., Kandalaft L.E., Hocquelet A., Orcurto A., Coukos G., Denys A., 2019/09. Cardiovascular and interventional radiology, 42 (9) pp. 1221-1229. Peer-reviewed.
[DOI][Pmid][serval:BIB_13E5E5B29D1D]
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10 p. 1832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0144F5D289B5]
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach.
Nikolaou M., Nikolaou G., Digklia A., Pontas C., Tsoukalas N., Kyrgias G., Tolia M., 2019. Integrative cancer therapies, 18 p. 1534735419827090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CA340C972534]
Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures.
Degrauwe N., Hocquelet A., Digklia A., Schaefer N., Denys A., Duran R., 2019. Frontiers in pharmacology, 10 p. 450. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_871EAEDDCDA1]
2018
 
Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems.
Loriaud A., Denys A., Seror O., Vietti Violi N., Digklia A., Duran R., Trillaud H., Hocquelet A., 2018/12. International journal of hyperthermia, 34 (8) pp. 1171-1178. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9CCBAE07143]
 
Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.
Vietti Violi N., Duran R., Guiu B., Cercueil J.P., Aubé C., Digklia A., Pache I., Deltenre P., Knebel J.F., Denys A., 2018/05. The lancet. Gastroenterology & hepatology, 3 (5) pp. 317-325. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75DA07F6AE94]
2017
 
Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.
Skafida E., Kokkali S., Nikolaou M., Digklia A., 2017/06. Expert review of anticancer therapy, 17 (6) pp. 537-543. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_73DC47A54E2B]
 
Carcinome hépatocellulaire avancé : nouveautés de la thérapie systémique et place du traitement local ? [Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy]
Parisod L., Duran R., Denys A., Digklia A., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1032-1034. Peer-reviewed.
[Pmid][serval:BIB_B80B0D598281]
 
Establishing a formal sarcoma center for children and adults at the Lausanne University Hospital
Bosisio Francesca, Matter Maurice, Fortin Aurélie, CHUV Multidisciplinary Sarcoma Team, 2017. Swiss Knife 3 pp. 16-19. Peer-reviewed.
[serval:BIB_B13928EA1DBE]
2016
 
Centre des sarcomes : un nouvel outil pour améliorer la prise en charge du patient et soutenir la recherche [Sarcoma centres : a necessary tool in the management of patients and for research.]
Cherix S., Vauclair F., Morattel B., Vautrin M., Matter M., Montemurro M., Digklia A., Letovanec I., Omoumi P., Saucy F. et al., 2016/12/14. Revue medicale suisse, 12 (543) pp. 2172-2176. Peer-reviewed.
[Pmid][serval:BIB_B4139C33D819]
 
The cutting edge of metastatic melanoma therapy.
Digklia A., Michielin O., 2016/09. Melanoma management, 3 (3) pp. 217-229. Peer-reviewed.
[DOI][Pmid][serval:BIB_DC8359A7EB02]
Traitement curatif du cancer de l'oesophage: consensus multidisciplinaire multicentrique [Curative treatment for esophageal cancer: results of a multidisciplinary consensus]
Allemann P., Mantziari S., Wagner D., Digklia A., Ozsahin E., De Bari B., Dorta G., Godat S., Montserrat F., Sempoux C. et al., 2016/06/15. Revue medicale suisse, 12 (523) pp. 1165-1169. Peer-reviewed.
[URN][Pmid][serval:BIB_58E6531A0AFA]
Advanced gastric cancer: Current treatment landscape and future perspectives.
Digklia A., Wagner A.D., 2016. World Journal of Gastroenterology, 22 (8) pp. 2403-2414. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9CE953713724]
2015
 
Eribulin for heavily pre-treated metastatic breast cancer patients.
Digklia A., Voutsadakis I.A., 2015/08/20. World journal of experimental medicine, 5 (3) pp. 194-199. Peer-reviewed.
[DOI][Pmid][serval:BIB_12396576EA72]
Nouveautés et perspectives dans la prise en charge des cancers colorectaux et gastriques avancés [News and perspectives in the treatment of advanced gastric and colorectal cancers]
Diciolla A., Cristina V., De Micheli R., Digklia A., Wagner A.D., 2015/05/20. Revue medicale suisse, 11 (475) pp. 1122,1124-1126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6313089CA2F4]
2014
 
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.
Digklia A., Voutsadakis I.A., 2014/11/20. World journal of experimental medicine, 4 (4) pp. 58-67. Peer-reviewed.
[DOI][Pmid][serval:BIB_F692C709E268]
 
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Digklia A., Tzika E., Voutsadakis I.A., 2014. Journal of Oncology Pharmacy Practice, 20 (2) pp. 146-148. Peer-reviewed.
[DOI][Pmid][serval:BIB_EAFEDE77DFF7]
Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.
Digklia A., Voutsadakis I.A., 2014. Obstetrics and Gynecology Science, 57 (6) pp. 457-463. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FF661047267E]
Unusual presentation of cerebral venous sinus thrombosis associated with contraceptive usage.
Panos G.D., Panos L.D., Digklia A., Hafezi F., Gatzioufas Z., 2014. Journal of Ophthalmic and Vision Research, 9 (2) pp. 281-284. Peer-reviewed.
[URN][Pmid][serval:BIB_F211B2B9A892]
2013
 
Targeted treatments for metastatic esophageal squamous cell cancer.
Digklia A., Voutsadakis I.A., 2013. World Journal of Gastrointestinal Oncology, 5 (5) pp. 88-96. Peer-reviewed.
[DOI][Pmid][serval:BIB_0D8DC0748A82]
2012
 
Acute cerebrovascular accident after Cisplatin treatment in a patient taking letrozole.
Digklia A., Voutsadakis I.A., 2012. Chemotherapy, 58 (6) pp. 435-438.
[DOI][WoS][Pmid][serval:BIB_CE4992C52F2C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University